NanoViricides, Inc. (NYSE American: NNVC) (“NanoViricides” or the “Company”), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape, today announced the closing of its previously announced registered direct offering (the “Offering”) of 1,333,334 million shares of common stock (or pre-funded warrants in lieu thereof), together with accompanying warrants to purchase 1,333,334 common shares (the “Offering”). The common shares are being sold in combination with an accompanying full warrant (with each whole warrant being exercisable into one common share of the Company). Each whole warrant has an exercise price of US$1.75 per share and will expire three years from the date of issuance. The Company received aggregate gross proceeds of approximately $2,000,000 from the Offering, before deducting placement agent fees and other related expenses.
D. Boral Capital LLC acted as the exclusive placement agent for the Offering.
Lucosky Brookman served as counsel to the company.
